Holen Sie sich die Stockscreener-App
96.27
0.86%
0.7546
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock - Defense World
Revolution Medicines (NASDAQ:RVMD) CFO Sells $273,868.44 in Stock - Defense World
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $427,965, According to a Recent SEC Filing - marketscreener.com
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD - Investing.com
Anders, Revolution Medicines CFO, sells $273k in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,010 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,073 Shares - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 12,871 Shares - MarketBeat
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock By Investing.com - Investing.com India
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 2,753 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock - MarketBeat
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD By Investing.com - Investing.com India
Revolution Medicines exec Kelsey sells $427,964 in stock By Investing.com - Investing.com India
Anders, Revolution Medicines CFO, sells $273k in RVMD stock By Investing.com - Investing.com India
Revolution Medicines CEO Goldsmith sells $1.28 million in stock - Investing.com
Revolution Medicines exec Kelsey sells $427,964 in stock - Investing.com
Revolution Medicines COO Horn sells $455,918 in shares - Investing.com
Revolution Medicines CEO Goldsmith sells $1.28 million in stock By Investing.com - Investing.com Australia
Wei Lin, chief medical officer, sells $206k in Revolution Medicines - Investing.com
Revolution Medicines (NASDAQ: RVMD) CMO sells 2,073 shares for tax withholding - Stock Titan
Revolution Medicines (RVMD) officer sells 4,302 shares under 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) director sells 12,871 shares in 10b5-1 trade - Stock Titan
Revolution Medicines (RVMD) COO pre-planned sale tied to RSU tax - Stock Titan
CFO of Revolution Medicines (NASDAQ: RVMD) sells 2,753 shares - Stock Titan
Revolution Medicines (RVMD) counsel sells 2,958 pre-planned shares - Stock Titan
Revolution Medicines (RVMD) insider sale under 10b5-1 plan for RSU taxes - Stock Titan
Morgan Stanley schedules sale of RVMD (NASDAQ: RVMD) RSUs, prior insider sales listed - Stock Titan
Revolution Medicines (RVMD) Among Top Biotech M&A Targets - GuruFocus
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech - Seeking Alpha
Revolution Medicines, Inc. (RVMD) net loss widens amid progress on clinical trial programs - MSN
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Stifel Reiterates Revolution Medicines (RVMD) Buy Recommendation - MSN
Wells Fargo Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Revolution Medicines Secures $2 Billion Flexible Financing Deal with Royalty Pharma - MSN
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Bitget
Revolution Medicines Showcases RAS(ON) Inhibitor Pipeline Advances at AACR Annual Meeting 2026 - Quiver Quantitative
Revolution Medicines to Showcase Progress Across RAS(ON) - GlobeNewswire
Revolution Medicines brings lung and pancreatic cancer trial data to AACR 2026 - Stock Titan
Algert Global LLC Boosts Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD: Jefferies Raises Price Target for Revolution Medicines to $140 | RVMD Stock News - GuruFocus
RVMD SEC FilingsRevolution Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Acquired by HighVista Strategies LLC - MarketBeat
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):